Choose which factors matter most to you when selecting a lipid-lowering medication.
If you’ve been prescribed Tricor (fenofibrate) to tame high triglycerides, you’re probably wondering whether there’s a better or cheaper option. fenofibrate belongs to the fibrate family, drugs that primarily lower triglycerides and raise “good” HDL cholesterol. In South Africa the brand name Tricor is the most common way patients receive fenofibrate, but the molecule itself is sold under many generics worldwide. This article lines up Tricor against the most frequently prescribed alternatives - statins, ezetimibe, omega‑3 fatty acids and niacin - so you can see where it shines, where it falls short, and which factors matter most when you and your doctor choose a lipid‑lowering plan.
Tricor is the commercial name for the drug fenofibrate, a prescription medication approved by the FDA in 1998 for treating hypertriglyceridaemia. It is indicated for patients with triglyceride levels above 5mmol/L (≈440mg/dL) who are at risk of pancreatitis, or for those whose LDL‑cholesterol is already controlled by a statin but still have high TG. In South Africa it is prescribed under the National Health Insurance scheme and is also available as a generic powder.
Fenofibrate activates the nuclear receptor PPAR‑α (peroxisome proliferator‑activated receptor‑alpha). This switches on genes that increase fatty‑acid oxidation, enhance lipoprotein lipase activity, and reduce hepatic production of VLDL particles. The net effect is a 30‑50% drop in triglycerides and a 5‑15% rise in HDL‑cholesterol. Unlike statins, fenofibrate has only a modest impact on LDL‑cholesterol (usually a 5‑10% reduction).
To make a fair side‑by‑side look, we weigh each medication on six criteria that matter to most patients and clinicians:
Statins inhibit HMG‑CoA reductase, the rate‑limiting step in cholesterol synthesis. They are the first‑line choice for anyone with elevated LDL or established heart disease.
Atorvastatin (Lipitor) is a high‑potency statin that can shave 50‑60% off LDL at a 80mg dose. Rosuvastatin (Crestor) is similarly potent but often better tolerated at lower doses. Simvastatin (Zocor) is older, cheaper, and works well for moderate LDL reductions.
Ezetimibe targets the NPC1L1 transporter in the small intestine, cutting dietary cholesterol uptake by about 15‑20%. It is typically added to a statin when LDL remains above target. Alone, it drops LDL 15‑20% with virtually no effect on triglycerides.
Omega‑3 fatty acids (prescription‑grade EPA/DHA) lower triglycerides by 20‑30% and modestly raise HDL. They work through reduced hepatic VLDL synthesis and improved clearance. Muscle pain is rare, but the biggest downside is price, especially for the brand‑name Vascepa®.
Niacin (vitaminB3) can raise HDL by up to 30% and cut triglycerides 20‑25%. However, flushing, itching, and potential liver toxicity have pushed it out of first‑line therapy in most guidelines.
Drug | Class | Typical dose | Triglyceride ↓ | LDL ↓ | Common side‑effects | Monthly cost (ZAR) |
---|---|---|---|---|---|---|
Tricor (fenofibrate) | Fibrate | 145mg PO daily | 30‑50% | 5‑10% | GI upset, ↑ liver enzymes | ≈300 |
Atorvastatin | Statin | 10‑80mg PO daily | 5‑15% | 50‑60% | Muscle aches, ↑ liver enzymes | ≈250 |
Rosuvastatin | Statin | 5‑40mg PO daily | 5‑15% | 45‑55% | Muscle aches, rare rhabdo | ≈300 |
Ezetimibe | Absorption inhibitor | 10mg PO daily | ~0% | 15‑20% | Diarrhoea, fatigue | ≈350 |
Omega‑3 (EPA/DHA) | Fish‑oil derivative | 2‑4g PO daily | 20‑30% | ~5% | Fishy after‑taste, mild GI | ≈500 |
Niacin | Vitamin B3 | 500‑1000mg PO daily | 20‑25% | ~5% | Flushing, itching, liver risk | ≈150 |
Use the following quick‑check to narrow down the best option:
Always discuss these choices with your doctor, who will factor in your full lipid panel, other meds, kidney function, and personal cost preferences.
Yes, many doctors combine a fibrate with a low‑to‑moderate potency statin when both high triglycerides and high LDL need treatment. Monitoring liver enzymes and muscle enzymes is essential.
Fenofibrate (Tricor) typically reduces TG by 30‑50%, which is higher than statins (5‑15%) and similar to high‑dose EPA/DHA fish‑oil (20‑30%).
Generally yes. Fenofibrate does not significantly affect blood glucose, but it can raise serum creatinine, so kidney function should be checked regularly.
Statins inhibit cholesterol synthesis in muscle cells, which can lead to myopathy in susceptible individuals. Fenofibrate works through a different pathway (PPAR‑α), so the muscle‑related side‑effect profile is lower.
No strict restrictions, but a low‑fat, balanced diet helps the drug work faster and reduces the chance of stomach upset.
Written by Neil Hirsch
View all posts by: Neil Hirsch